GlassScriptPhysician profile
Kweon Stambaugh
NPI 1063494185
$2,818.87
in general payments reported to CMS, 2019-2025
17 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $67.82 · 2021: $13.82 · 2022: $245 · 2023: $193 · 2024: $1,135 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $802 · Food and Beverage: $671 · Gift: $3.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $801.61 |
| Food and Beverage | $671.35 |
| Gift | $3.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $1,045.06 | 2020-2024 | |
| Medical Device Business Services, INC. | $961.46 | 2019 | |
| Aerin Medical INC. | $205.46 | 2023-2025 | |
| Genzyme Corporation | $148.15 | 2019-2024 | |
| Novo Nordisk INC | $91.31 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $90.71 | 2022 | |
| Smith+Nephew, INC. | $40.33 | 2022 | |
| Stryker Corporation | $37.94 | 2023 | Scopis Ent |
| Merck Sharp & Dohme LLC | $30.35 | 2023 | |
| Glaxosmithkline, LLC. | $27.93 | 2024 | Nucala |
| Shionogi INC | $27.90 | 2023 | Fetroja |
| Optinose US, INC. | $22.73 | 2023 | |
| Abbvie INC. | $21.40 | 2023 | Dalvance |
| Paratek Pharmaceuticals, INC. | $20.42 | 2023 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $16.37 | 2024 | Dupixent |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.76 | 2019 | |
| Intersect Ent, INC. | $15.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kweon Stambaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.